Internal Server Error

About Alger

Alger is a venture capital firm founded in 1964. It is primarily based out of New York City, United States. As of Dec 2025, Alger has invested in 7 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series F round of Impulse Dynamics Overall, Alger portfolio has seen 2 unicorns and 2 acquisitions including key companies like SandboxAQ, Forte Biosciences and Intarcia. A lot of funds co-invest with Alger, with names like Yann LeCun sharing a substantial percentage of its portfolio. Alger has team of 58 people including 2 partners.
Key Metrics
Team Members
Portfolio Locations
Rounds of Entry
Series B, Post IPO & 4 more
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months

Alger's List of Top Investments

Alger has a portfolio of 7 companies, including 2 unicorns. Their most notable investments are in ChoiceStream and SandboxAQ.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 1 other sectors, across stages such as Series B, Post IPO  and 4 more. Here is the list of top investments by Alger:
Developer of quantitative artificial intelligence models for various industry applications. The company provides large quantitative models rooted in science and engineered for impact. These models offer real-world solutions with clear outputs and reduced uncertainty. The company's models are deployed in areas such as drug discovery, new chemicals and materials, cybersecurity, navigation, and medical diagnostics.

Key facts about SandboxAQ

Impulse Dynamics is focussed on developing solutions for the treatment of Chronic Heart Failure. They have developed, Optimizer IV, a minimally invasive implantable device based on novel Cardiac Contractility Modulation (CCM) technology, and delivers non-excitatory electric pulses. The Optimizer is CE is FDA approved.

Key facts about Impulse Dynamics

Forte Biosciences is a developer of therapeutic solutions for treating inflammatory skin diseases. The company has developed its lead topical product, FB-401 made of strains of a commensal gram-negative bacteria called as Roseomonas mucosa to treat inflammatory skin disease.

Key facts about Forte Biosciences

Intarcia Therapeutics offers a drug delivery platform technology. The product is a subcutaneous osmotic mini-pump containing the necessary volume of the drug. Once implanted under the skin, water from the extracellular fluid enters the device and osmotic pressure drives a piston which delivers the drug.

Key facts about Intarcia

Developer of antiviral and other therapeutics using proprietary drug discovery platform. The company's research is based on its proprietary cell-free protein synthesis or CFPSS drug discovery platform allows for the identification of small molecule drugs, which may be missed by traditional pharma screening methods. The company has successfully produced potent compounds which display activity against multiple strains of many viral families including lead series of molecules that are effective antiviral agents against influenza, HIV, and HCV.

Key facts about Prosetta Biosciences

  • Founded Year: 2003
  • Location: San Francisco (United States)
  • Annual Revenue: 0 - ₹10 Cr as on Mar 31, 2025
  • Stage: Series D
  • Total Funding till date: $35.1M
  • Employee Count: 23 as on Aug 31, 2026
  • Investors: Takeda, Alger and 2 Others
  • Latest Funding Round: Series D, Nov 20, 2015, $*****

Alger's Investments by Stage

Alger has made 2 investments in Series B stage with an average round size of $10.9M, 1 investment in Post IPO stage with an average round size of $37.9M and 1 investment in Series A stage with an average round size of $300M.
Here are Alger's investments by stage:
Stage of entry
No. of Investments
Series B
2
Post IPO
1
Series A
1
Series D
1
Series E
1
Others
1
Breakdown of Alger's investments by stage of entrySeries B (2)Post IPO (1)
Note: We have considered here, only first round of investments

Alger's Investments by Sector

Alger has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Artificial Intelligence - Industry Applications, Enterprise Infrastructure and High Tech. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 2 Software companies and at least 1 company focusing on AI-Native.
Here are Alger's investments by sector:
Sector
No. of Investments
Life Sciences
5
Enterprise Applications
2
Artificial Intelligence - Industry Applications
1
Enterprise Infrastructure
1
High Tech
1
Others
1
Breakdown of Alger's investments by sectorsLife Sciences (5)Enterprise Applic... (2)
Note: We have considered here, only first round of investments

Alger's Investments by Geography

Alger has made most investments in United States (7).

Alger's recent investments

Alger has not made any investment in 2026 so far.
Here are the most recent investments by Alger:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Dec 10, 2025
United States
Series F
4532
Apr 04, 2025
United States
Series E
4502
  [+10]
Dec 18, 2024
United States
Series A
6557
  [+11]
Nov 20, 2024
United States
Post IPO
4963
  [+5]
Feb 05, 2024
United States
Series E
7088

Unicorns in Alger's Portfolio

Alger has 2 unicorns in its portfolio - SandboxAQ and Intarcia. The most recent unicorn in their portfolio is SandboxAQ. It became a unicorn in 2024.
Here is a list of unicorns in Alger's portfolio:
Tracxn Score
Company
Short Description
Founded year
Sector
Location
Company Stage
First Investment/ Acquisition Details
66
Developer of quantitative artificial intelligence models for various industry applications
2022
Palo Alto
Series E
gxijccs
47
Provider of osmotic pump for subcutaneous drug delivery
1995
Boston
Series J
{ucbgps

Acquired companies in Alger's Portfolio

2 companies from Alger's portfolio have been acquired. The most recent acquisition was Forte Biosciences in Jul 2026 by argenx for $*****.
Here are Alger's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Jul 27, 2026
Nov 20, 2024
Post IPO
4012
Dec 21, 2016
Aug 15, 2014
Series B
9034

Team profile of Alger

Alger has a team of 58 members including 2 Partners and 34 Principals located in United States, United Kingdom and 1 more location. Alger's team does not sit on the board of any company as of now.

Co-investors of Alger

Over the past 12 years, 77 investors have co-invested in Alger's portfolio companies. This includes funds and angels.

  • Invested before Alger: Schmidt’s, Breyer Capital and 41 others have invested in rounds before Alger. There is 1 company where Schmidt’s has invested before Alger and 1 company where Breyer Capital has invested before Alger.
  • Top Co-investors of Alger: 19 investors entered a company along with Alger. These include investors like Yann LeCun (1 company).
  • Invested after Alger: A total of 15 investors have invested in Alger's portfolio after their investments. Top Investors include Alphabet (1 company), BNP Paribas (1 company) and Nvidia (1 company).

Recent News related to Alger

•
Alger Concentrated Equity ETF Q3 2026 Portfolio UpdateSeeking Alpha•Nov 06, 2026•Alger
•
Alger Growth & Income Fund Q3 2026 Portfolio UpdateSeeking Alpha•Nov 03, 2026•Alger
•
•
Alger Mid Cap Focus Fund Q2 2026 Portfolio ReviewSeeking Alpha•Jul 29, 2026•Alger
•
Alger Focus Equity Fund Q2 2026 CommentarySeeking Alpha•Jul 24, 2026•Alger
•
•
Alger Spectra Fund Q2 2026 Portfolio UpdateSeeking Alpha•Jul 21, 2026•Alger
View all news related to Alger

FAQs about Alger

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford